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Purpose: The present study aimed to clarify prevalence and profile of depressive mixed state (DMX) in depressed 
individuals with autism spectrum disorder (ASD). 
Patients and methods: The Quick Inventory of Depressive Symptomatology Self-Report Japanese version (QIDS- 
SR-J) and global assessment of functioning (GAF) were administered to 182 consecutive patients (36 ASD and 
146 non-ASD subjects) with a major depressive episode (MDE). DMX was categorically diagnosed according to 
the criteria for mixed depression (MD) by Benazzi and mixed features (MF) specifier by DSM-5. Severity of DMX 
was assessed by the self-administered 12-item questionnaire for DMX (DMX-12). Clinical backgrounds and 
incidence/severity of DMX were compared between the ASD and non-ASD groups. 
Results: ASD patients showed higher prevalence of MD than non-ASD patients (36.1% versus 18.5%). Mood 
lability, distractibility, impulsivity, aggression, irritability, dysphoria and risk-taking behavior as mixed symp-
toms were more prevalent in ASD patients than those in non-ASD patients, together with higher scores of total 
DMX-12 and its disruptive emotion/behavior cluster. Multiple regression analysis revealed significant contri-
bution of ASD to the disruptive emotion/behavior symptoms. 
Conclusion: Careful monitoring and management of potential DMX are warranted in depressed ASD individuals.   
1. Introduction 
Depressive mixed state (DMX) during a major depressive episode 
(MDE) can often be overlooked as depressed patients rarely state their 
inner instability as their spontaneous expression(Kondo et al., 2016). In 
fact, the prevalence of DMX during MDE appears to be low (3.2-7.5%) 
(Perugi et al., 2015; Takeshima and Oka, 2015) when relatively strict 
criteria for mixed features (MF) specifier by DSM-5 (American Psychi-
atric Association, 2013) are applied to mixed psychopathology. On the 
other hand, Benazzi’s definition of mixed depression (MD), including 
distractibility, irritability and agitation as nonspecific but frequent 
mixed symptoms (Benazzi, 2008a, 2007, 2002), seems to cover the 
broader concept of clinically relevant DMX. The prevalence of MD 
ranged from 12.8% to 32.3% even in patients with major depressive 
disorder (Benazzi, 2008b; Takeshima and Oka, 2015). Accordingly, the 
prevalence of DMX widely varies depending on categorical diagnoses 
used in different studies. Thus, we have recently developed a 
self-administered 12-item questionnaire for DMX (DMX-12) as a 
dimensional assessment tool for severity of DMX (Shinzato et al., 2019). 
We also conducted a confirmative study for construct validity of the 
DMX-12 (Shinzato et al., 2020), demonstrating that selected compo-
nents of the DMX-12 were closely associated with such established 
categorical criteria for depressive mixed state as “mixed depression” by 
Benazzi (Benazzi, 2007) and “mixed features” by DSM-5 (American 
Psychiatric Association, 2013). 
Since DMX has previously been regarded as a mixture of both manic 
and depressive components in its psychopathology (Fornaro et al., 
2012), various reports have suggested close association between bipo-
larity and DMX (Benazzi, 2008b; Inoue et al., 2015; Takeshima and Oka, 
2015, 2013). We have also clarified that bipolarity can have a positive 
* Corresponding author at: Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa, Japan. 
E-mail address: hshin530@hiroshima-u.ac.jp (H. Shinzato).   
1 Equally contributed author. 
Contents lists available at ScienceDirect 
Psychiatry Research 
journal homepage: www.elsevier.com/locate/psychres 
https://doi.org/10.1016/j.psychres.2021.113932 
Received 5 August 2020; Accepted 8 April 2021   
Psychiatry Research 300 (2021) 113932
2
effect on severity of DMX, which can further affect symptoms of 
disruptive emotion/behavior (aggression, irritability, dysphoria, and 
risk-taking behavior) by using the DMX-12 (Shinzato et al., 2019). These 
findings clearly suggest that bipolar disorder is an important risk factor 
in the development of DMX. However, possible involvement of other 
psychiatric comorbidities including neurodevelopmental disorders in 
DMX during MDE have not been fully clarified yet. 
Nowadays, autism spectrum disorder (ASD) is no longer perceived as 
a rare condition in clinical settings as the prevalence of ASD is estimated 
to have risen to approximately 1% in adults in the general population 
(Brugha et al., 2011). It has been also demonstrated that comorbid ASD 
is found in 11-16% of first-visit adult patients with MDE (Takara and 
Kondo, 2014a, 2014b). Thus, an important clinical question here is how 
the presence of ASD affects depressive psychopathology when ASD in-
dividuals suffer from clinical depression. It is a well-known fact that ASD 
patients often undergo irritability, hyperactivity and emotional dysre-
gulation as listed in the Aberrant Behavior Checklist (Aman et al., 1985) 
and the Emotion dysregulation Inventory (Mazefsky et al., 2018). Recent 
studies have shown that higher risks of psychiatric comorbidity and 
suicidality are found even in subthreshold autistic traits (Dell’Osso et al., 
2019a,b). In our previous study (Takara and Kondo, 2014b), agitation 
was the most significant contributor to suicidal attempts among 
depressed adults, and its incidence was extremely high (89%) among 
ASD suicide attempters. Since ASD and DMX have symptomatologic 
commonality like increased irritability, agitation, emotional dysregu-
lation, and potential suicidality, it is possible that ASD individuals may 
reveal traits of mixed psychopathology during MDE. 
Depressive disorder is relatively common among ASD individuals. Its 
prevalence widely ranges from 2.5% to 47.1% (Hossain et al., 2020), but 
is approximately four times higher than that in the general population 
(Hudson et al., 2019). Likewise, co-occurrence of bipolar disorders is 
estimated to range from 6% to 21.4% (Vannucchi et al., 2014) or from 
3% to 6% (Lai et al., 2019) according to two systematic reviews, both of 
which appear to cite higher rates compared to what is expected in the 
general population. It has also been pointed out that young ASD subjects 
without an intellectual disability have a 5.8-8.5 times higher risk for 
bipolar disorders (Selten et al., 2015). Therefore, a close relationship 
may exist between ASD and bipolarity. This also implies that bipolar 
components may be more easily intruded into depressive psychopa-
thology as DMX symptoms in depressed individuals with ASD. 
However, there have been very few studies that look into intensively 
dealing with detailed psychopathology among depressed individuals 
with ASD or that have directly investigated the association between ASD 
and DMX during MDE. Thus, in the present study, we aimed to clarify 
the prevalence and profile of DMX in depressed individuals with ASD 
and the possible contribution ASD may have to mixed psychopathology. 
2. Methods 
2.1. Subjects 
This study was conducted at the University of the Ryukyus Hospital 
from June 2014 to Dec 2019. A total of 301 new consecutive outpatients 
with suspected MDE presented to our outpatient clinic and were diag-
nosed by two experienced psychiatrists according to the DSM-5 diag-
nostic criteria (American Psychiatric Association, 2013). The 298 
patients whose native language was Japanese were included in the 
study, two of the whom withdrew their consent during the study. 
Eighty-six of the patients were determined not to have had a major 
depressive episode (schizophrenia: 7, delusional disorder: 1, generalized 
anxiety disorder: 9, obsessive-compulsive disorder: 2, panic disorder: 2, 
social anxiety disorder: 2, somatic symptom and related disorders: 2, 
bulimia nervosa: 1, dissociative disorder: 2, alcohol, methamphetamine, 
and benzodiazepine use disorder: 8, insomnia disorder: 1, major neu-
rocognitive disorder: 1, and the rest were adjustment disorders or mood 
disorders that did not meet a current depressive episode e.g., in 
remission). 
Two hundred and ten patients fulfilled the diagnostic criteria for a 
DSM-5 major depressive episode (American Psychiatric Association, 
2013), 28 of whom (4 with some kind of use disorder, 3 with neuro-
cognitive disorder, 8 with neurodevelopmental disorders other than 
ASD, and 13 with physical comorbidities that may affect the brain’s 
organs: 5 with human immunodeficiency virus infection, 2 with epi-
lepsy, 1 with amyotrophic lateral sclerosis, 1 with postoperative pitui-
tary tumor, 1 with systemic lupus erythematosus, 1 with post liver 
transplant, 1 with multiple sclerosis, and 1 with pregnancy) were 
excluded from the analysis. As a result, 182 patients were included in the 
analysis. 
Subjects finally consisted of 182 outpatients with MDE (69 males and 
113 females; 44.0 ± 17.9 years between the ages of 13-85). The same 
experienced psychiatrists confirmed MDE according to the DSM-5 
diagnostic criteria (American Psychiatric Association, 2013) and 
further classified MDE into unipolar depression (n = 133) and bipolar 
and related disorders (n = 49). Diagnosis of ASD was also made by the 
same trained psychiatrists according to the criteria of DSM-5 (American 
Psychiatric Association, 2013). Patients with 
substance-related/addictive disorders or neurocognitive disorders were 
not enrolled in the present study. Since this study aimed to highlight the 
effect of ASD on DMX during MDE, participants who had apparent 
comorbidities with other neurodevelopmental disorders, e.g., intellec-
tual disability and attention deficit/hyperactivity disorder (ADHD) were 
excluded from the analyses. 
Only the subjects who had the ability to verbally communicate with 
others voluntarily participated in the study and gave written informed 
consent. For patients under the age of 18, written informed consent was 
taken not only from patients themselves but also from their parents. 
Data was anonymously treated during the study. Only coded and 
grouped data were used for analyses. Explanation for the purpose of the 
study, measures for protection of personal information, and the right to 
withdraw from the study were provided to each participant. This study 
protocol was conducted in accordance with the Declaration of Helsinki. 
The study protocol was approved by the Ethics Committee at the Uni-
versity of Ryukyus. 
2.2. Assessment 
The Quick Inventory of Depressive Symptomatology Self-Report 
(Rush et al., 2003) Japanese version (QIDS-SR-J) and global assess-
ment of functioning (GAF) (Endicott et al., 1976) were administered to 
each participant. 
DMX was categorically diagnosed according to criteria for MD by 
Benazzi (Benazzi, 2008a, 2008b, 2002) and MF by DSM-5 (American 
Psychiatric Association, 2013). Severity of DMX was assessed by 
DMX-12 (Appendix 1), which we recently developed (Shinzato et al., 
2020, 2019). Internal consistency of its three subscales were guaranteed, 
i.e., spontaneous instability” (Cronbach’s α = 0.868), “vulnerable 
responsiveness” (Cronbach’s α = 0.826) and “disruptive emotion/be-
havior” (Cronbach’s α = 0.769) (Shinzato et al., 2019). 
2.3. Statistical analyses 
Association between ASD and MD or MF were statistically analyzed 
by either Chi square test or Fisher’s exact test. The association between 
ASD and gender, education level, and bipolarity were similarly tested 
using Chi square. Group comparisons of clinical backgrounds (age, 
number of mood episodes, duration of illness, and duration of current 
episode), scores of QIDS-SR-J, GAF, and symptoms of the DMX-12 were 
performed by independent t-test. 
Multiple regression analyses were conducted to evaluate contribu-
tion of abovementioned background factors, QIDS-SR-J, GAF, and 
presence/absence of ASD as independent variables to total DMX-12 and 
its subscale scores as dependent variables. Dummy variables were used 
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for gender (0: female, 1: male), education level (0: high school or lower, 
1: university or upper), bipolarity (0: major depressive disorder, 1: bi-
polar disorder), and ASD (0: non-ASD, 1: ASD). 
A two-tailed P value less than 0.05 was regarded as statistically 
significant. SPSS software 16.0 J for Windows (SPSS Japan Inc., Tokyo, 
Japan) was used to carry out the statistical analyses. 
3. Results 
Thirty-six patients (19.8%) were found to have ASD. Thus, the group 
comparisons were made between patients with ASD (n = 36) and those 
without ASD (n = 146). Regarding clinical backgrounds, no significant 
differences were found in gender distribution, number of mood epi-
sodes, duration of illness, duration of current episode, and education 
level between the ASD and non-ASD groups (Table 1). Although ASD 
patients had a higher proportion of bipolarity (38.9%) than non-ASD 
patients (24.0%), the difference did not reach a significant level (P =
0.07) (Table 1). Meanwhile, age range was found to be lower (younger) 
in the ASD group than that in the non-ASD group (35.6 ± 12.9 versus 
46.1 ± 18.3 years, P = 0.001) (Table 1). 
There were 40 cases (22.0%) with MD and 8 cases (4.4%) with MF 
among the overall patients (Table 2). ASD patients showed a higher 
prevalence of MD compared to non-ASD patients (36.1% versus 18.5%, 
P = 0.022) whereas differences in prevalence of MF remained marginal 
between the two groups (11.1% versus 2.7%, P = 0.05) (Table 2). 
Among the DMX-12 symptoms, mood lability, distractibility, 
impulsivity, aggression, irritability, dysphoria, and risk-taking behavior 
were more prevalent in ASD patients than those in non-ASD patients 
(Table 3). Although the scores of QIDS-SR-J and GAF did not signifi-
cantly differ between the ASD and non-ASD groups, the ASD group 
showed greater severity of total DMX-12 and its disruptive emotion/ 
behavior cluster than the non-ASD group (Table 4). 
Multiple regression analysis revealed negative correlations of age 
with total DMX-12 (β = − 0.249, P = 0.001) and its three subscale scores 
of spontaneous instability (β = − 0.149, P = 0.049), vulnerable 
responsiveness (β = − 0.278, P = 0.001), and disruptive emotion/ 
behavior (β =− 0.278, P = 0.001) while the score of QIDS-SR-J was 
positively correlated with total DMX-12 (β = 0.505, P = 0.001) and its 
three subscale scores of spontaneous instability (β= 0.504, P = 0.001), 
vulnerable responsiveness (β = 0.354, P = 0.001), and disruptive 
emotion/behavior (β = 0.370, P = 0.001). ASD (β = 0.161, P = 0.020), 
bipolarity (β = 0.170, P = 0.031), and educational level (β = − 0.138, P 
= 0.040) were also significantly linked to the disruptive emotion/ 
behavior cluster of the DMX-12 (Table 5). 
4. Discussion 
Assessments of co-occurring psychiatric conditions is complicated 
and challenging in ASD because of overlapping symptoms, diagnostic 
overshadowing, and ambiguous presentation of symptoms in ASD in-
dividuals (Rosen et al., 2018). In fact, some ASD individuals are not good 
at expressing their inner emotions due to their poor capability of verbal 
and non-verbal communication (Lartseva et al., 2015). Such negative 
emotion can be easily masked by their constricted or flat affect and 
lowered help-seeking attitude, leading to underdiagnosis of depression 
including DMX by clinicians. Interestingly, it was suggested that 
life-time depression rates in ASD individuals could be significantly 
Table 1 
Comparisons of clinical backgrounds between patients with and without autism 
spectrum disorder.   





Age (years) 35.6 ± 12.9 46.1 ± 18.3 0.001 
Female gender (%) 58.3 % 63.0% 0.604 
Number of mood episodes 3.1 ± 3.0 3.0 ± 3.0 0.901 
Duration of mood disorder (year) 8.4 ± 7.9 6.2 ± 7.9 0.149 
Duration of current depressive episode 
(month) 
19.6 ± 30.3 12.7 ± 41.8 0.368 
High Educational level 47.2% 35.6% 0.209 
Bipolarity 38.9 % 24.0% 0.071  
Table 2 
Association between autism spectrum disorder and mixed depression/mixed features specifier.    
Mixed depression Mixed features specifier Total   
+ - + -  
Autism spectrum disorder + 13 23 4 32 36 (19.8%)  
- 27 119 4 142 146 (80.2%)  
Total 40 (22.0%) 142 (78.0%) 8 (4.4%) 174 (95.6%) 182   
Odds: 2.491 (95%CI: 1.121-5.534)  Odds: 4.438 (95%CI: 1.053-18.692)     
Chi square test: P=0.022  Fisher’s exact test: P=0.050    
Table 3 
The DMX-12 symptom scores between patients with and without autism spec-
trum disorder DMX-12.   
Autism Spectrum Disorder   
Present (n=36) Absent (n=146) P 
Spontaneous instability 
Restlessness 1.64 ± 0.99 1.63 ± 1.04 0.964 
Racing/crowded thought 2.08 ± 1.00 1.97 ± 1.00 0.553 
Mood lability 1.92 ± 1.00 1.48 ± 1.03 0.022 
Inner tension 2.06 ± 0.95 1.95 ± 0.96 0.536 
Distractibility 2.31 ± 0.79 1.83 ± 1.05 0.003 
Impulsivity 1.61 ± 0.99 1.12 ± 1.03 0.011 
Vulnerable responsiveness 
Hypersensitivity 2.19 ± 1.01 2.01 ± 0.95 0.296 
Overreactivity 2.11 ± 0.95 1.87 ± 1.02 0.199 
Disruptive emotion/behavior 
Aggression 0.89 ± 1.06 0.49 ± 0.82 0.042 
Irritability 1.58 ± 1.05 1.19 ± 1.01 0.040 
Dysphoria 1.97 ± 0.94 1.54 ± 0.96 0.017 
Risk-taking behavior 0.97 ± 0.97 0.52 ± 0.88 0.008 
DMX-12: the 12-item questionnaire for quantitative assessment of depressive 
mixed state. 
Table 4 
Comparisons of depression severity, functional impairment and depressive 
mixed state between patients with and without autism spectrum disorder.   
Autism Spectrum Disorder   
Present (n = 36) Absent (n = 146) P 
QIDS-SR-J 17.2 ± 4.7 16.1 ± 5.3 0.236 
GAF 46.5 ± 9.8 48.0 ± 11.4 0.467 
Total DMX-12 21.3 ± 7.6 17.6 ± 8.0 0.012 
Spontaneous instability 11.6 ± 4.0 10.0 ± 4.8 0.060 
Vulnerable responsiveness 4.3 ± 1.8 3.9 ± 1.8 0.206 
Disruptive emotion/behavior 5.4 ± 3.1 3.7 ± 2.8 0.002 
QIDS-SR-J: Quick Inventory of Depressive Symptomatology Self-Report Japa-
nese version, GAF: Global Assessment of Functioning, DMX-12: the 12-item 
questionnaire for quantitative assessment of depressive mixed state. 
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elevated with older age (18 and over), higher intelligence (IQ>100), 
assessment with structured interviews, and information from self-report 
(Hudson et al., 2019). This suggests that self-rating questionnaires with 
a standardized format can be more helpful compared to unstructured 
medical interviewing by clinicians in the hopes of catching a sign of 
depression and the related mixed symptoms. This may also be the case 
with adult ASD patients who fall within normal intelligence scores since 
self-rating scales seem to be less stressful than face-to-face verbal inquiry 
from others especially when expressing their emotional problems. The 
DMX-12 focuses on inner mixed manifestations which can be conve-
niently self-evaluated by ASD individuals. Therefore, the DMX-12 would 
be requisite for effective and efficient screening of mixed psychopa-
thology in depressed ASD individuals. 
Apart from prototypical depression symptoms, ASD individuals may 
exhibit more atypical presentations of depression like increased irrita-
bility, anxiety, aggression, and self-injury as specific manifestations of 
depressive psychopathology (Greenlee et al., 2016; Pezzimenti et al., 
2019). Such unstable and externalizing symptoms are also observed as 
nonspecific but frequent symptoms of DMX (Benazzi, 2008a, 2007, 
2002) although symptomatologic commonality between ASD and DMX 
has never been directly confirmed to date. The present study firstly 
showed more prevalent mixed symptoms like mood lability, distracti-
bility, impulsivity, aggression, irritability, dysphoria, and risk-taking 
behavior together with greater severity of DMX, especially its disrup-
tive emotion/behavior component, in depressed ASD individuals. 
Furthermore, ASD patients exhibited greater proportions of categori-
cally diagnosed DMX (MD as significant and MF as marginal) compared 
to non-ASD patients. These findings strongly suggest that a close rela-
tionship exists between ASD and DMX. 
Meanwhile, the close association between ASD and bipolar disorder 
has been consistently suggested in several studies demonstrating greater 
comorbidity (Lai et al., 2019; Vannucchi et al., 2014) and higher risk 
(Selten et al., 2015) of bipolar disorders in ASD individuals. One lon-
gitudinal follow-up study (Borue et al., 2016) demonstrated that youth 
with both ASD and bipolar disorder exhibited an earlier onset of mood 
symptoms and more frequent mixed symptom presentation such as 
distractibility and racing thoughts compared with youth who only had 
bipolar disorder. Furthermore, a clinical trial of citalopram, a selective 
serotonin reuptake inhibitor, resulted in behavioral activation (hyper-
activity, distractibility, impulsivity, disinhibition, and intrusive 
behavior) as unwanted effects in ASD children (5-17 years) without any 
mood problems (King et al., 2009). These findings imply that presence of 
autistic traits may provoke development of mixed psychopathology 
under potential or clinical bipolarity. In contrast, only a marginal rela-
tionship between ASD and bipolarity in the present study suggests that 
autistic traits are primarily involved in mixed psychopathology 
independent of bipolarity. 
Possible interaction between ASD and DMX consequently reminds us 
of enhanced suicidal risk in depressed ASD adults. Surprisingly, a clin-
ical cohort study with ASD individuals revealed that two-thirds of them 
self-reported suicidal ideation while one-third of them actually planned 
or attempted suicide in the 9-year study period (Cassidy et al., 2014). 
The same authors also demonstrated that suicidal ideation and suicide 
plans/attempts were more prevalent in ASD individuals comorbid with 
depression than those without depression (Cassidy et al., 2014). Mean-
while, a significant correlation was found between the number of 
life-time suicide attempts and DMX according to the Research-Based 
Diagnostic Criteria (Popovic et al., 2015). These findings clearly indi-
cate that combined psychopathology with ASD and DMX can produce 
synergistic effects on acceleration of suicidal risk. In fact, our previous 
study (Takara and Kondo, 2014b) has pointed out that agitation during 
MDE is the most significant risk factor for suicidal attempts, which is 
also observed as a symptom of both ASD and DMX. The same study also 
revealed a sharp contrast in presence of agitation between suicide 
attempters (89%) and non-attempters (11%) among depressed ASD 
adults, suggesting that agitation is a potent promoter for suicidal action 
in depressed adults with ASD (Takara and Kondo, 2014b). Therefore, 
psychomotor agitation should be discussed and monitored for risk 
management of suicidality when treating depressed patients with ASD. 
Evidence for effective medication against DMX is disappointingly 
lacking. From a clinical point of view, use of mood stabilizers with an 
antimanic property (e.g., valproic acid and lithium) and second- 
generation antipsychotics (e.g., olanzapine, quetiapine, lurasidone, 
and aripiprazole) are recommended while antidepressants should be 
avoided if possible (Takeshima, 2019). There is a paucity of evidence 
and lack of guidelines for recommended pharmacotherapy of DMX in 
ASD. Even in purely depressive episodes of ASD, validity for the use of 
antidepressants are still controversial (Vannucchi et al., 2014). Mean-
while, antipsychotics (e.g., risperidone and aripiprazole) (Sharma et al., 
2018)and mood stabilizers like lithium (Vannucchi et al., 2014) have 
been reported to be effective for symptoms associated with irritability, 
agitation, and impulsivity in ASD patients irrespective of mood symp-
toms. Taking these findings together, it may be safer to avoid antide-
pressants and use mood stabilizers and/or atypical antipsychotics 
instead for DMX in ASD although these hypothetical recommendations 
needs to be confirmed by future controlled studies in these specific 
subjects. 
This study has several limitations as follows. First, the results were 
obtained from a relatively small number of ASD subjects. Second, 
severity of DMX was substituted with assessment of its frequency on the 
basis of self-reported dimensional scales by the DMX-12. Third, repro-
ducibility of the present results should be confirmed in other ethnic 
Table 5 
Multiple regression analyses of possible determinants for total and subscale scores of the DMX-12.  
Instability DMX-12 (Total) Spontaneous instability Vulnerable Responsiveness Disruptive Emotion/behavior  
В P β P В P В P 
Age -0.249 0.001 -0.149 0.049 -0.278 0.001 -0.278 0.001 
Gender 0.006 0.927 0.035 0.619 -0.150 0.033 0.056 0.404 
Educational level -0.069 0.283 -0.027 0.691 -0.019 0.787 -0.138 0.040 
Number of mood 
episodes 
-0.057 0.507 -0.112 0.220 -0.008 0.929 0.027 0.757 
Duration of Illness -0.001 0.989 0.047 0.621 -0.035 0.711 -0.056 0.537 
Duration of current 
episode 
-0.012 0.850 -0.032 0.644 0.001 0.988 0.017 0.802 
Bipolarity 0.148 0.052 0.107 0.184 0.111 0.171 0.170 0.031 
ASD 0.103 0.123 0.073 0.305 0.013 0.851 0.161 0.020 
QIDS-SR-J 0.505 0.001 0.504 0.001 0.354 0.001 0.370 0.001 
GAF 0.012 0.859 0.089 0.209 -0.020 0.772 -0.098 0.154  
R=0.610, R2=0.372 
F=9.646, P=0.001  
R=0.537, R2=0.289 
F=6.619, P=0.001  
R=0.530, R2=0.281 
F=6.377, P=0.001  
R=0.577, R2=0.333 
F=8.136, P=0.001  
β: standardized partial regression coefficient. Dummy variables were used for gender (0: female, 1: male), education level (0: high school or lower, 1: university or 
upper), bipolarity (0: major depressive disorder, 1: bipolar disorder) and ASD (0: non-ASD, 1: ASD). 
Y. Zamami et al.                                                                                                                                                                                                                                
Psychiatry Research 300 (2021) 113932
5
populations by using the English version of the DMX-12. Fourth, the risk 
of suicidality was not directly evaluated in relation to ASD and DMX in 
this study. Nevertheless, it should be noted that there is a close rela-
tionship between ASD and DMX, and that this combination (ASD+DMX) 
may lead to drastically enhanced suicidal risk. Careful monitoring of 
disruptive emotion/behavior symptoms are warranted when treating 
ASD individuals during MDE. 
5. Conclusions 
ASD exhibits higher prevalence of MD and more frequent disruptive 
emotion/behavior symptoms during MDE. Careful monitoring and 
management of potential DMX are warranted in depressed individuals 
with ASD as they may be more prone to DMX during MDE. 
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